Login / Signup

Carbon-11 patents (2012-2022): synthetic methodologies and novel radiotracers for PET imaging.

Nerella Sridhar GoudPriti SinghSanam Tulja
Published in: Expert opinion on therapeutic patents (2022)
 = 20.4 min), it is widely used in PET radiotracer development due to its direct insertion into bioactive compounds and less isotopic dilution unlike other positron emitters like fluorine-18. Various synthons can be easily generated using the primary and secondary carbon-11 precursors . The carbon-11 radiotracers provide target-oriented information associated with the pharmacology, and physiological conditions of the disease status. Various protocols and automated methods were adapted for easy and convenient synthesis of carbon-11 radiotracers. The PET advances drug development and clinical trials by revealing biological target engagement, proof of mechanism, pharmacokinetic, and pharmacodynamic profiles of new drug candidates using selective radiotracers.
Keyphrases
  • pet imaging
  • positron emission tomography
  • clinical trial
  • computed tomography
  • machine learning
  • deep learning
  • pet ct
  • emergency department
  • high resolution
  • phase ii
  • electronic health record